<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/019F0CD2-FDD7-42A3-89A1-600286E65412"><gtr:id>019F0CD2-FDD7-42A3-89A1-600286E65412</gtr:id><gtr:name>Myriad RBM USA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256"><gtr:id>4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256</gtr:id><gtr:name>Imagen Biotech</gtr:name><gtr:address><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE6BFA8F-2830-4CB9-BC35-5D5DEA490640"><gtr:id>FE6BFA8F-2830-4CB9-BC35-5D5DEA490640</gtr:id><gtr:name>Aurinia Pharmaceuticals Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0C4013D-24CC-4F07-98FE-9F9AEA971BA3"><gtr:id>E0C4013D-24CC-4F07-98FE-9F9AEA971BA3</gtr:id><gtr:name>Aeirtec</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>School of Medical Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/019F0CD2-FDD7-42A3-89A1-600286E65412"><gtr:id>019F0CD2-FDD7-42A3-89A1-600286E65412</gtr:id><gtr:name>Myriad RBM USA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256"><gtr:id>4D8C3EF0-2A9D-4001-81E2-F0A7AAA54256</gtr:id><gtr:name>Imagen Biotech</gtr:name><gtr:address><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE6BFA8F-2830-4CB9-BC35-5D5DEA490640"><gtr:id>FE6BFA8F-2830-4CB9-BC35-5D5DEA490640</gtr:id><gtr:name>Aurinia Pharmaceuticals Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0C4013D-24CC-4F07-98FE-9F9AEA971BA3"><gtr:id>E0C4013D-24CC-4F07-98FE-9F9AEA971BA3</gtr:id><gtr:name>Aeirtec</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A88DF793-DE72-4667-89EF-A1033FB0B0D8"><gtr:id>A88DF793-DE72-4667-89EF-A1033FB0B0D8</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McHugh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0C2DD187-C91B-499E-A128-26297E8A3D34"><gtr:id>0C2DD187-C91B-499E-A128-26297E8A3D34</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Norman</gtr:otherNames><gtr:surname>Bruce</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/01882632-1970-4184-993E-B00468A3E9E0"><gtr:id>01882632-1970-4184-993E-B00468A3E9E0</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Tom</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/098914C4-FBD1-4414-918E-EF68D8766089"><gtr:id>098914C4-FBD1-4414-918E-EF68D8766089</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:surname>Payne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8D79684-12A6-43C0-B1D4-01B63705028E"><gtr:id>A8D79684-12A6-43C0-B1D4-01B63705028E</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/019FDE0D-1BE2-4EB3-AAD1-C35B73E767A6"><gtr:id>019FDE0D-1BE2-4EB3-AAD1-C35B73E767A6</gtr:id><gtr:firstName>Miriam</gtr:firstName><gtr:surname>Wittmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8057343-F807-4B73-A002-995C5C19CBEA"><gtr:id>A8057343-F807-4B73-A002-995C5C19CBEA</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Alan</gtr:otherNames><gtr:surname>Isenberg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/616D7A43-AD5E-4B56-907B-0FC06106E3EA"><gtr:id>616D7A43-AD5E-4B56-907B-0FC06106E3EA</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:otherNames>B</gtr:otherNames><gtr:surname>Lightstone</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D9D643AA-B70C-4DFC-B3FB-7316A2150168"><gtr:id>D9D643AA-B70C-4DFC-B3FB-7316A2150168</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Ainsworth</gtr:surname><gtr:orcidId>0000-0002-2187-9195</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/491A5874-115C-4E1F-A4C6-D73C4166F590"><gtr:id>491A5874-115C-4E1F-A4C6-D73C4166F590</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Jayne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/91242383-D07B-4A20-B1D0-B32872619EE9"><gtr:id>91242383-D07B-4A20-B1D0-B32872619EE9</gtr:id><gtr:firstName>Marina</gtr:firstName><gtr:surname>Botto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/44B4E2FB-3F1F-471C-BF9F-BF1C27C7464E"><gtr:id>44B4E2FB-3F1F-471C-BF9F-BF1C27C7464E</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Randolph</gtr:otherNames><gtr:surname>Ehrenstein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7FBD0D70-392B-4D99-AAF2-9154ED5E7CB7"><gtr:id>7FBD0D70-392B-4D99-AAF2-9154ED5E7CB7</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Vyse</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7D32529B-DD4F-4E8A-AACE-69956147DC12"><gtr:id>7D32529B-DD4F-4E8A-AACE-69956147DC12</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Emery</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9A4F674B-FB00-4106-894D-92BE0806B6BE"><gtr:id>9A4F674B-FB00-4106-894D-92BE0806B6BE</gtr:id><gtr:firstName>Darren</gtr:firstName><gtr:surname>Plant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B272710A-AD32-4F95-9608-C01C25225F0B"><gtr:id>B272710A-AD32-4F95-9608-C01C25225F0B</gtr:id><gtr:firstName>Vern</gtr:firstName><gtr:surname>Farewell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B063A25D-0ED6-4E2D-99AF-B3D6457726A3"><gtr:id>B063A25D-0ED6-4E2D-99AF-B3D6457726A3</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Caleb</gtr:otherNames><gtr:surname>Pickering</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/59A4352A-54BB-4A8E-8A72-2E60A26BB0C9"><gtr:id>59A4352A-54BB-4A8E-8A72-2E60A26BB0C9</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:orcidId>0000-0002-6355-3361</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1FC66050-4664-4B03-9BA9-8C4DA121E555"><gtr:id>1FC66050-4664-4B03-9BA9-8C4DA121E555</gtr:id><gtr:firstName>Amin</gtr:firstName><gtr:surname>Rostami-Hodjegan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/36553161-C6DF-4030-8396-A89927765ABF"><gtr:id>36553161-C6DF-4030-8396-A89927765ABF</gtr:id><gtr:firstName>Yanick</gtr:firstName><gtr:surname>Crow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5D9DC774-14FE-4845-B021-1579E9B1D169"><gtr:id>5D9DC774-14FE-4845-B021-1579E9B1D169</gtr:id><gtr:firstName>Mattia</gtr:firstName><gtr:surname>Prosperi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8A66049D-A707-4E78-A632-9550C9761B76"><gtr:id>8A66049D-A707-4E78-A632-9550C9761B76</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:otherNames>Pamela</gtr:otherNames><gtr:surname>Gordon</gtr:surname><gtr:orcidId>0000-0002-1244-6443</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8CF6487B-7ACE-4AF7-9DFD-765D596433FE"><gtr:id>8CF6487B-7ACE-4AF7-9DFD-765D596433FE</gtr:id><gtr:firstName>Li</gtr:firstName><gtr:surname>Su</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72DC2B63-8B96-4B63-84E1-52D775ED665D"><gtr:id>72DC2B63-8B96-4B63-84E1-52D775ED665D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Beresford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6423B82E-E350-41AC-9B52-F6A18E75F522"><gtr:id>6423B82E-E350-41AC-9B52-F6A18E75F522</gtr:id><gtr:firstName>David Lester</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0690F4D6-742B-4E93-97BB-F722B2745DFB"><gtr:id>0690F4D6-742B-4E93-97BB-F722B2745DFB</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Lunt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/20A5F2CD-E4B3-4B35-97F8-42737304AAAA"><gtr:id>20A5F2CD-E4B3-4B35-97F8-42737304AAAA</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:surname>Vital</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A95EEF00-1119-41F9-8103-C4121DE96A33"><gtr:id>A95EEF00-1119-41F9-8103-C4121DE96A33</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>D'Cruz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM01665X%2F1"><gtr:id>5C2EDD4D-B951-4522-987D-0A89D419F579</gtr:id><gtr:title>MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M01665X/1</gtr:grantReference><gtr:abstractText>Systemic Lupus Erythematosus (SLE) is a chronic incurable disease caused by a person's immune system attacking organs and tissues such as the joints, skin, kidneys and brain. SLE affects one in 2000 individuals in the UK. Currently, treatment is selected based on a doctor's experience and on a 'trial and error' approach. Many agents take at least 6 months to show maximum improvement during which patients often require large steroid doses. It is recognised that long-term complications of lupus are associated with both ongoing 'grumbling' disease activity and chronic steroid use. Standard immunosuppressives such as mycophenolate mofetil (MMF) have had response rates of 50-60% in clinical trials and newer, more targeted' biological therapies such as rituximab, belimumab and epratuzumab also report response rates in trials of 40-60%. Clinical experience and a number of studies have however suggested that there are certain patients who respond very well to particular treatments. The goals of a stratified approach therefore would be to allow doctors to maximise major response rates whilst avoiding / minimising chronic steroid therapy and aligning therapy selection better with our understanding of the key disease process in an individual patient. Our consortium will identify and apply in the clinic, factors that predict excellent response to therapy to allow doctors to increase the early use of 'most effective' therapies. This 'stratified' approach will also improve the success of future trials of new treatments for lupus which to date has had a suboptimal record. 
To do this we will combine expertise from clinical and laboratory-based investigators, and link these with researchers working in the pharmaceutical industry. Our focus will be to identify factors that predict which patients do extremely well on any particular lupus treatment. We will start by focusing on a small number of drugs. As we demonstrate that this approach works well, we will be able to expand this method to other lupus treatments which are currently in development. We plan to re-analyse data already available from a number of large studies ongoing in the UK and internationally as well as to re-analyse data from previous lupus clinical trials. From these studies we will look for key predictive factors; such factors may include the type of lupus, genetic markers that the patient inherited and results of blood tests . In order to examine this question in even more detail, we plan to set up two parallel studies; one in patients with skin rashes due to lupus and one in patients with kidney involvement. In both these studies we will take biopsies to examine the affected tissue and also take blood and urine samples on a regular basis. These samples will be used to look in detail at how cells, proteins and other molecules change over time after a patient has been treated with a particular therapy. Combining this detailed information with the information gained from the larger studies we aim to better predict excellent levels of response to treatment.
This information will be used to help develop devices and/or computer programmes for the clinic to help find the most appropriate and effective treatment choices for patients with lupus. We plan to test our results in a clinical trial to examine whether this approach actually has more benefit for patients. Running alongside this, we will study the economic costs of lupus to the health care system as well as the costs of lupus to the individual and society. We anticipate that treating the right patient with the right drug at the right time will help control lupus better in individual patients, improve their survival rates and reduce their needs for need for steroid treatment. We also anticipate that this approach will significantly improve the quality of life of patients with lupus whilst also providing financial saving for the healthcare and benefits system.</gtr:abstractText><gtr:technicalSummary>Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting approx. 16,000 people in the UK. It is highly heterogeneous: each patient presents with a unique fingerprint of organs involved, severity, and response to therapy. The clinical heterogeneity is paralleled by a range of underlying genotypic and immune function abnormalities. A number of new therapies, with different mechanisms of action, have been developed. Overall response rates are only 40-60% but subsets of patients respond very well to each drug. Current therapy is based on a 'trial and error' approach often involving glucocorticoid co-therapy. Delayed and poor control of inflammation results in organ damage, cardiovascular disease and glucocortocoid toxicity. We aim to fundamentally improve care for SLE patients by identifying key endotypes associated with remission and low disease activity (LDA) on particular therapies.
Our goal requires a co-ordinated and co-operative approach. Our consortium combines expertise from academia with pharmaceutical and small and medium enterprise (SMEs) partners to identify predictors of response to exemplar therapies. Clinical and genotypic predictors of response will be sought by analysis of existing data from large studies. Two parallel prospective studies assessing tissue, blood and urine from patients with skin or renal lupus will study immunophenotypic predictors of response. These discoveries will be used to develop near-patient devices and algorithms to select therapy in clinic. We will test the benefit and cost-effectiveness of this stratification approach in trials.
Using the right drug at the right time will improve control of inflammation for people with SLE. Long-term benefits will be improved survival, improved quality of life and reduced glucocorticoid requirements, whilst providing financial savings for health and social care. MASTERPLANS will be the international model of best practice in delivering stratified medicine to SLE patients.</gtr:technicalSummary><gtr:potentialImpactText>Immediate beneficiaries will be SLE patients who will be offered treatment that is targeted on the basis of disease mechanisms and biomarkers that predict high levels of clinical response to particular drug treatments. A limitation of current standard of care therapy is the dependence on chronic glocucortocoid use to control disease on a day-to-day basis. Deploying other therapies to maximise efficacy will contribute to reducing this burden for patients. This offers the likelihood of better disease control, fewer flares, improved quality of life and reduce long-term morbidity. 
A predictive algorithm and biomarker-based approach to SLE therapy will significantly influence payers and healthcare policy makers. In the short term we will target the right treatment to the right patient for the treatments that we have studied. In the medium-long term this investigative model for evaluating and positioning drugs better will be an exemplar of best practice whereby other treatments can be evaluated within the treatment paradigm for SLE.
For the pharmaceutical industry our approach will be a key driver for a change in the way SLE trials are performed. Entry criteria for clinical trials are currently based on fulfilling classification criteria and a predetermined level of disease activity. This approach has resulted in a number of trials that have failed to achieve their primary end-point when randomising 'all-comers' without any regard to specific mechanisms. The approach we will take, using predictive biomarkers and algorithms, will shift the paradigm to a mechanism-based approach that will increase the statistical power of clinical trials and increase the likelihood of success in subsets of patients with SLE. Inclusion across the regulatory age groups including children and expertise within the consortium in supporting delivery of Paediatric Investigational Plans will be a key additional benefit for Industry.
The consortium will contribute to and build momentum around, stratified medicine in the UK. In particular it will build on the UK's recognised strengths in the area of immune-inflammatory diseases. A consortium focused on SLE will help to further build strength and capacity to complement that already underway in RA and other inflammatory diseases. It will also complement the work of the NIHR Translational Research Partnerships that seek to link UK academic researchers with industry to bring through novel therapeutics for condition such as lupus early in their development cycle. This synergy will be enhanced greatly by this award. The consortium also supports the aims and objectives of the MRC Clinical Pharmacology Training programmes which seeks to bring through a new generation of Clinical Pharmacologists. Stratified Medicine is a major theme of the TRP and the Clinical Pharmacology programmes and so by linking with such initiatives, our consortium will help increase the visibility of the UK research infrastructure focused on stratified medicine and inflammatory conditions of importance. 
Globally, SLE is a disease with a major ethnic gradient being more common and severe in the developing world including people of Chinese, African and Hispanic ancestry. Whilst our consortium is based in the UK, we will have access to international cohorts through patients involved in industry-sponsored global clinical trial development programmes as well as the SLICC cohort. This will allow our studies and the models of analysis developed to have a global relevance. This will also mean we will have an impact in areas of the world where lupus is more common, prognosis is poor and where sequential use of therapies that may not work are unaffordable. A biomarker driven selective use of agents may however be cost-effective in such an environment and allow a wider population of patients to benefit from these new therapeutic developments.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-12-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-06-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4185920</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Myriad RBM USA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MASTERPLANS Consortium - Myriad RBM</gtr:description><gtr:id>79130A24-9496-4BD6-AE8B-8B780FE16985</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd99a7514514.01676135-1</gtr:outcomeId><gtr:partnerContribution>Myriad RBM has a long-standing and a well established expertise in inflammatory diseases. In particular they have expertise in providing multiplex assay systems to study a range of potentially important cytokines biomarkers that can be adapted to a bespoke disease specific panels that can track disease activity and may serve as predictive biomarkers for response / non-response. In addition they have a unique ex vivo system (TruCulture) to assess cytokine expression in whole blood in response to addition of a drug of interest. Such predictive data combined with clinical and other biomarker data will help develop predictive algorithms for selecting therapy for patients in a timely manner. 
It will also provide the data by which new testing platforms and algorithms can be brought to the clinic. 
Myriad RBM can uniquely contribute expertise in the development and delivery of these near patient testing system which is already part of a portfolio in advanced stages of clinical development and are already deployed for other purposes in other clinical settings already (Vectra DA for RA).</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Imperial College of Science, Technology and Medicine, London</gtr:description><gtr:id>805AF2F9-58B1-40C8-B18A-5B01F8F78FC7</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8a9c8aed21.47328588-1</gtr:outcomeId><gtr:partnerContribution>The Imperial College of Science, Technology and Medicine will provide significant input to the Consortium including leading on the analysis of renal biopsy specimens and co-ordination of the renal substudy.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epistem</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Epistem Limited</gtr:description><gtr:id>BE827E01-BD67-4757-A153-8118293B99D5</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd95433419a0.61969487-1</gtr:outcomeId><gtr:partnerContribution>Epistem have expertise in providing gene expression and genotypic information to help provide predictive biomarkers for patient stratification and therapeutic decision-making. They have extensive experience in validating and developing RNA signature assays and DNA genotyping assays. Epistem's unique strength is the provision of assays to a CE-IVD marked Point-of-Care platform, Genedrive, to be utilised in a decentralised setting. Epistem will work with the consortium to take key biomarker findings to Point-of-Care systems. Epistem can uniquely contribute expertise in the delivery of this near patient testing system.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium -University of Birmingham</gtr:description><gtr:id>85208109-8C45-494A-99A7-4145FDBD5CDA</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd557be43638.76506691-1</gtr:outcomeId><gtr:partnerContribution>The University of Birmingham will take a signifiacnt leadership role in metabolomics and PPI/E for the consortium</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Medical Research Council</gtr:description><gtr:id>E9B0BB0A-74AA-477F-B1C4-58A48CAFB3D9</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8ff7cb23c6.13882627-1</gtr:outcomeId><gtr:partnerContribution>The Medical Research Council will provide significant input to the Consortium including leading on statistical modelling of integrated datasets with an emphasis on multistate modelling of disease activity over time based on the BILAG2004 scoring system.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - UCB Biopharma SPRL</gtr:description><gtr:id>BBEDD75A-29ED-43AE-B9F4-4419A0D307AA</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd9adeaee705.52079363-1</gtr:outcomeId><gtr:partnerContribution>UCB will patient level data and baseline biomarker samples from epratuzumab (anti-CD22) trials including the Phase 2 and the Phase 3 EMBODY studies. Control arms will be used to populate MMF analyses. 

UCB will analyse blood samples using their in house CyTOF2 system (not widely available in the UK) to identify and test the optimal cell surface phenotypic markers and intracellular readouts in the patient study. 

WS6: Epratuzumab HRQOL data will also be used in the development of health economic modelling.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MASTERPLANS Consortium - Medimmune Limited</gtr:description><gtr:id>A5580FF9-7818-427C-B1F8-51E44A2BD095</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd98738688c0.08633652-1</gtr:outcomeId><gtr:partnerContribution>MedImmune have a specific interest in SLE and have a strong pipeline of agents currently in development targeting this therapeutic area. Several of these trials are already in the field targeting the interferon pathway (Anti IFN -MED1545, anti IFNAR -MED1546). MedImmune have also developed a type I interferon gene signature which they are using within these clinical trials. MedImmune will bring this knowledge to the study of interferon dynamics during the prospective arms of the study using MMF and or B-cell targeted therapies. 
MedImmune also has expertise in proteomic and complex flow cytometry of lupus samples which will be used to complement WP1-4.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - University of Bath</gtr:description><gtr:id>671F2FDC-6654-42C4-AC71-488910554FE8</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56d88444118814.49967320-1</gtr:outcomeId><gtr:partnerContribution>The University of Bath will provide significant input to the Consortium including co-ordination of the serological factors in our consortium studies</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MASTERPLANS Consortium - GlaxoSmithKline</gtr:description><gtr:id>8F16C68E-B5EA-4403-839D-AFDEC78E71B3</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd9737768380.49281284-1</gtr:outcomeId><gtr:partnerContribution>GSK - provision of anonymised patient level data and biomarker samples from key pivotal trials conducted using belimimab (anti-BLyss)(BLISS 52, n= 865 and BLISS 76, n=819). 
Data from the control arms of trials will be used to populate the MMF analysis across a number of clinical trial (CT) programs (WS5). 
The health related QOL data generated from active and placebo arms of these trials will be used in the development of health economic modelling (WS6).</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Pfizer Limited</gtr:description><gtr:id>84191C4C-69F7-49EA-9F5D-3546875FF0BD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd9a1ee75700.44036584-1</gtr:outcomeId><gtr:partnerContribution>Pfizer will support the consortium in developing clinical pharmacology modelling and support management of the overall consortium including statistical support.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - King's College, London</gtr:description><gtr:id>3F05C6D0-3B1C-4949-8E73-F00F29CF5D12</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8b7dd3e6d9.94936604-1</gtr:outcomeId><gtr:partnerContribution>King's College, London will provide significant input to the Consortium including leading in the genetic analysis of cohort data and also working with Manchester to lead and co-ordinate the large cohort data analysis.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - University of Liverpool</gtr:description><gtr:id>F1E82CA1-0F93-4328-A217-84E26D11C3FD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8dd14be0f5.83695815-1</gtr:outcomeId><gtr:partnerContribution>The University of Liverpool will provide significant input to the Consortium including leading on planning and assessment of young adults with SLE as well as studying urinary biomarkers in SLE and substudies examining neutrophil function</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine and Health</gtr:department><gtr:description>MASTERPLANS Consortium - University of Leeds</gtr:description><gtr:id>10C60BA3-8BA0-4147-B375-03317A8D4BC4</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8d45dceb02.91559396-1</gtr:outcomeId><gtr:partnerContribution>The University of Leeds will provide significant input to the Consortium including leading on the overall prospective study and specifically the cutaneous SLE study. They will analyse cutaneous biopsy data and also develop epidermal sampling analysis.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Divisions of Nephrology and Clinical Pharmacology</gtr:department><gtr:description>MASTERPLANS Consortium - University of Cambridge</gtr:description><gtr:id>ECA905C6-28A9-415D-91EE-55FA865A3988</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd8906027922.07223790-1</gtr:outcomeId><gtr:partnerContribution>The University of Cambridge will take a significant leadership role in co-ordinating PPI and PPE activities in the consortium and also advising on study design, future trials and funding opportunities through leadership of the Longevity Committee</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aeirtec</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Aeirtec Limited</gtr:description><gtr:id>8C0F22D5-F405-4E19-9863-1D595369B118</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd5722504c68.74963941-1</gtr:outcomeId><gtr:partnerContribution>For the purposes of the collaboration, The University of Manchester have access to the largest bank of annotated clinical samples in SLE in Europe and an established research activity in the disease. Additionally, through this consortium they will generate samples from intervention studies that would not otherwise be available. Aeirtec have proprietary technology that generates a uniquely ultra high level of customised multiplex immunoassay sensitivity. Many top of the hierarchy markers (eg low abundance early response cytokines) involved in inflammatory, immune and vascular disease exist at low abundance and require the level of sensitivity that Aeirtec's assay system provides to avoid the loss of sample marker data as 'below level of detection'. Aeirtec also have experience in distillation of marker panels for discrimination between disease strata and group response to treatment. The combined forces of large cohort sample banking and unparalleled custom multiplex assay sensitivity generates a unique platform for delineation of disease stratification and efficacy soluble protein marker panels in SLE.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organsation for the MASTERPLANS consortium</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imagen Biotech</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - Imagen Biotech Limited</gtr:description><gtr:id>C95C845F-02FA-4F55-9FF0-B4D43F205F2A</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd97cbf3da43.20038771-1</gtr:outcomeId><gtr:partnerContribution>Imagen Biotech will take compounds from the consortium (mycophenolic acid and monoclonal antibodies) and test using their adhesion assay in a high throughput manner using automated fluorescence microscopy (High Content Screening).</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aurinia Pharmaceuticals Inc</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>MASTERPLANS Consortium - Aurinia Pharmaceuticals Inc</gtr:description><gtr:id>F7A9F0ED-B038-4A8E-AA8B-C30A8DA59F13</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd947c461298.98366554-1</gtr:outcomeId><gtr:partnerContribution>Aurinia/Vifor will provide patient level data from key pivotal trials conducted using MMF (ALMS Trial programme). Data will be prepared cleaned and shared with the consortium through a database manager working within Aurinia.
The health related quality of life data generated from the active and placebo arms of these trials will also be used in the development of health economic modelling (WS6).
The consortium is uniquely placed to combine data from a number of sources focused on response to MMF and a major component of this data is held by Vifor from the ALMS trial programme that demonstrate the efficacy of MMF in the long-term management of patients with SLE. This provides an invaluable dataset that can be added to other observational cohort data from patients trials.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead organisation for the MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MASTERPLANS Consortium - University College London</gtr:description><gtr:id>FAA5D756-AA9E-4EA0-9E67-18E388A54DAF</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd90a4da40b2.47534493-1</gtr:outcomeId><gtr:partnerContribution>The University College of London will provide significant input to the Consortium including leading on peripheral blood immunophenotyping and analysis of lymphocyte subsets during therapy.</gtr:partnerContribution><gtr:piContribution>The University of Manchester is the lead partner for the MRC funded MASTERPLANS Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BSR Rare Disease Strategy</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1781F468-35A2-411F-B6B3-528E796CC68B</gtr:id><gtr:impact>Good round table discussion about improving clinical services for patients with rare rheumatic diseases including lupus and vasculitis and how stratified medicine initiatives ad SLE trials could be developed in this context

BSR to draft a report and policy position</gtr:impact><gtr:outcomeId>565e161a917af7.06916126</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Hammersmith Hospital Rheumatology Department's Patient Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4B1A50C0-114F-4EF3-882E-52635F9D7561</gtr:id><gtr:impact>This hospital is one of MASTERPLANS contributing members, they wanted to alert their patients to opportunities to get involved in participating in research. Some questions and discussions after the meeting.</gtr:impact><gtr:outcomeId>58c95f83e5c605.05686461</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.imperial.nhs.uk/our-locations/hammersmith-hospital</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>?	Presented at LUPUS EUROPE Annual Convention in Wurzburg, Germany</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B698081-606C-4FBA-8252-C3B1DDC3D18C</gtr:id><gtr:impact>annual conference of European network. MASTERPLANS patient collaborator spoke about MASTERPLANS activity from a personal perspective.</gtr:impact><gtr:outcomeId>58c95cbd07a2d7.15159060</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.lupus-europe.org/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR at 10 Portcullis House London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>433A3CD7-ECE3-4004-A1B0-7BA10A483F30</gtr:id><gtr:impact>This event at Parliament allowed me to engage with MPs and lords as well as colleagues to promote the work of the Manchester BRU and our work with the NIHR on MSK research</gtr:impact><gtr:outcomeId>56cf20be2634c7.19576137</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Precision Medicine Congress</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C1A835C6-A1DA-4816-A219-87E94F6FE998</gtr:id><gtr:impact>International conference, a Patient Panel was convened and Jane Dunnage from MASTERPLANS was one. Each patient introduced their respective activity, then questions were asked of the panel. Great interest in involving patients and models of collaboration. Requested to take part in further patient panels.</gtr:impact><gtr:outcomeId>58c95b5b40d976.16617433</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.terrapinn.com/conference/precision-medicine-congress-usa/index.stm</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immune mediated Inflammatory Diseases Workshop: Wellcome Trust</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>67B7D3C0-18FA-4F33-A4F5-FD9A1C67631D</gtr:id><gtr:impact>This 2 day workshop brought together a wide spectrum of experts across immune mediated diseases to discuss challenges and future opportunities to learn more about immune mediated conditions. Several potential collaborations were discussed</gtr:impact><gtr:outcomeId>58bde1ce48d357.70273652</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Immunopsychiatry Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>588EF03B-A063-4356-8946-D9A14081A16C</gtr:id><gtr:impact>An MRC hosted workshop in immune aspects of psychiatry and psychiatric disorders in chronic autoimmune diseases</gtr:impact><gtr:outcomeId>58bddc7d9dbfe8.07011549</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department of Health Precision Medicine Conference Dec 2015 London UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3D0527CE-A893-47E7-8088-6B44C805BF88</gtr:id><gtr:impact>This all day event drew together a number of key players in Precision Medicine in the UK. It included round-table discussions and presentations that promoted our consortium as well as allowing our patient partners to discuss the role of patients in developing such research and how patients can get fully involved in such consortia</gtr:impact><gtr:outcomeId>56dde980ee6ec1.19268202</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus UK Northern Ireland Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FCC5D170-2ADA-408F-A0E8-8893FA000063</gtr:id><gtr:impact>This talk updated patients and practitioners on new treatment for SLE and stratified medicine approaches to therapy</gtr:impact><gtr:outcomeId>56cf1f6f05b499.23063744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Lupus Congress Sept 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E9250827-B1A6-4087-B5C9-A50116670375</gtr:id><gtr:impact>This talk focused on Damage in SLE and how we can better prevent this and improve long-term outcomes in this condition</gtr:impact><gtr:outcomeId>58bdde0f4c39e3.18655150</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Precision medicine forum</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B008639-6881-4D07-A10D-C2B43BD59FB9</gtr:id><gtr:impact>The conference programme included a patient panel: Panel members briefly introduced their project (in my case, MASTERPLANS), then took questions from floor.
Also Involved with round table discussion looking at data use which occurred immediately prior to panel and received good feedback from both.</gtr:impact><gtr:outcomeId>58c95a3c800e75.75649021</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://precisionmedicineforum.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal National Hospital for Rheumatic diseases, Bath</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EC5CE4F2-4F78-48B0-9957-4F76BDE8E5EF</gtr:id><gtr:impact>Jane Batchelor, MASTERPLANS patient collaborator, spoke about the importance of patients being willing to enrol as participants in research and gave information on MASTERPLANS. Bath is one of recruiting hospitals for MASTERPLANS, patients were advised to contact lupus consultant for more information.</gtr:impact><gtr:outcomeId>58c95581b9d0e3.87196359</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.rnhrd.nhs.uk/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SLE Stratified Medicine Application workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16D1E937-2F88-4163-8459-6050A02EF9E3</gtr:id><gtr:impact>The wrokshop was to prepare for a grant application workshop and we had patient collaborators in our group who helped us to shape our thinking

We improved our grant interview preparation and understood better what was important to patients in what we were trying to do.</gtr:impact><gtr:outcomeId>545e2430d25409.34585193</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK JSLE Conference Liverpool Jan 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95C1561D-4BD1-4C7B-A216-31F625C8FA8C</gtr:id><gtr:impact>This meeting allowed patients to discuss participation in consortium activities and studies in particular how young adults could be involved as patient collaborators as well as participating in prospective studies</gtr:impact><gtr:outcomeId>56ddea46d4dbf1.85810882</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Session co-chair at Juvenile SLE Study Group 10th Anniversary conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>484DB6C0-95ED-4346-A48A-D85BA56D1A02</gtr:id><gtr:impact>Session on MASTERPLANS held during seminar. Juvenile lupus patients will be involved as participants. Discussion on use of data, use of samples and involving the young people in some of the planning activities</gtr:impact><gtr:outcomeId>58c95dbb161ac3.79274953</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.liverpool.ac.uk/translational-medicine/research/ukjsle/jsle/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC North-West News Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>405994AA-F8EF-432B-ADC7-8991CA3871E4</gtr:id><gtr:impact>I was interviewed by BBC North-West Tonight about our lupus research especially our focus on personalised medicine and our MRC and BRC funded work.</gtr:impact><gtr:outcomeId>58bde265ba8972.25576476</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Psoriasis Council Symposium, Munich September 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>252B81C2-0439-4399-9EAE-5708FD8B3540</gtr:id><gtr:impact>I spoke on P4 medicine in rheumatology and how such an approach can better address patient stratification</gtr:impact><gtr:outcomeId>58bddd01d4a957.63824814</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conservative Muslim Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>07042EC3-C8F7-4E4B-8AD2-2103D50D4DC6</gtr:id><gtr:impact>This meeting in the House of Lords gave me the opportunity to talk about arthritis and its burden in the community as well as new approaches to treatment and prevention</gtr:impact><gtr:outcomeId>56cf203e09bc33.42353912</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LUPUS News and Views magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60B3692F-C8E3-4250-B095-816E8A857835</gtr:id><gtr:impact>Article to update Lupus UK members about MASTERPLANS (with J Dunnage) 
Some members of LUPUS UK volunteered to be MASTERPLANS patient collaborators</gtr:impact><gtr:outcomeId>58c9aa924c2a28.98280225</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Stratified Medicine Consortia in Immune-Inflammatory Diseases Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>39788D64-82AD-496F-A324-8F6E0F376F61</gtr:id><gtr:impact>This workshop explored common characteristics across a number of key consortia and has helped to better understand common challenges in the mechanisms of these conditions as well as common methodological challenges</gtr:impact><gtr:outcomeId>58bddf3b30c727.41713554</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus Think Tank</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C185A3CA-A496-4DB7-8933-D04345F1F37D</gtr:id><gtr:impact>This is an international Think Tank that is hosted by UCB and several key opinion leaders to try and better understand SLE outcomes and SLE clinical trial shortcomings and opportunities for improving trial design</gtr:impact><gtr:outcomeId>58bddbfbdf6bd0.26755169</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus News and Views magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F48F2FA3-DBB1-40DE-8118-155A215DE292</gtr:id><gtr:impact>Magazine contains information on living with lupus, activities national and local, research, fund raising possibilities. Important for lupus patients to see what research is being carried out, esp. as LUPUS UK will be grant-funding for some of MASTERPLANS activity</gtr:impact><gtr:outcomeId>58c956952ba299.22832266</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.lupusuk.org.uk/</gtr:url><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Keele INSPIRE Student Research Day December 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2E9474F8-178A-45EB-9F13-819675971FB3</gtr:id><gtr:impact>I spoke at this event and discussed stratified medicine in SLE and what were learning about the current state of the art and how we can move this forward</gtr:impact><gtr:outcomeId>58bddfccdc1e70.70794760</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Precision Medicine UK: Collaboration Nation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BD6B71CC-1F97-4429-9963-44925ADAAF1D</gtr:id><gtr:impact>Awareness raising about MASTERPLANS particularly the patient collaboration 'model'
Good interaction with other panel members and facilitator, plus some contact with audience members at the end of the meeting</gtr:impact><gtr:outcomeId>58c9aa0e296aa5.25194964</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MASTERPLANS - Manchester Patient Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6AC3D8EF-CB88-4E59-8376-92B3F080C173</gtr:id><gtr:impact>This 4 hour meeting sought to update local patients who expressed an interest in collaborating with the Consortium. We were able to invite patients to help out further with the Consortium following this meeting</gtr:impact><gtr:outcomeId>56dde84ca46295.69369550</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chapel Allerton Hospital Leeds</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E5200918-BF1A-45FE-A5FF-9D09512BB5EB</gtr:id><gtr:impact>Consultants spoke about their clinic and Researchers presented details of their research Inc. MASTERPLANS. Jane Dunnage (MASTERPLANS PPI Chair) spoke about the importance of patients getting involved in research in general and explained a little about MASTERPLANS.</gtr:impact><gtr:outcomeId>58c95738106bb8.18978748</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.leedsth.nhs.uk/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LUPUS UK Trustees meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBDEB7F7-4769-40A6-87D3-FF660B65C0C9</gtr:id><gtr:impact>Awareness raising about MASTERPLANS; discussion on how LUPUS UK can contribute to the project. Some members of the LUPUS UK trustees volunteered to be MASTERPLANS patient collaborators</gtr:impact><gtr:outcomeId>58c95ec16443e0.85089848</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.lupusuk.org.uk/</gtr:url><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LUPUS UK Council meetings</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>56794829-28D4-4C6B-8056-25659FB6CEB3</gtr:id><gtr:impact>Details of how patients will be involved in MASTERPLANS Consortium both as collaborators and participants. Funding requested for add-on research. Subsequently how activity is progressing.</gtr:impact><gtr:outcomeId>58c958a6328550.05779936</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.lupusuk.org.uk/</gtr:url><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LUPUS UK Council meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DEDAECE1-E455-425F-927D-8C13A1732B9B</gtr:id><gtr:impact>25 attendees but they represent the national membership. Council members will circulate information in their local group newsletter/website which should reach 2000
Awareness raising about MASTERPLANS
Some members of the LUPUS UK Council volunteered to be MASTERPLANS patient collaborators</gtr:impact><gtr:outcomeId>58c9ab53300e63.89016652</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Manchester Biomedical Research Centre</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>EA51659F-C256-4A7C-AD1B-F613A37081AD</gtr:id><gtr:outcomeId>58bdcb1f945684.01780894</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lupus UK</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>LUPUS UK</gtr:fundingOrg><gtr:fundingRef>NK</gtr:fundingRef><gtr:id>CAEDA835-71EC-47CF-A8D9-DB864D85E20D</gtr:id><gtr:outcomeId>56cf1e57a9bf94.02304708</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This is a national observational study of SLE patients starting on biological therapies. It recruits from 25 centres currently and has recruited 500 patients to date</gtr:description><gtr:id>A4529CC9-6067-481E-8A24-9452E2EB2E3E</gtr:id><gtr:impact>This register supports the ongoing access to biologics for SLE in the UK as it collects prospective data and informs future policies in this area. It is also an example of the use of unlicensed medications and how to gather data whilst allowing ongoing access</gtr:impact><gtr:outcomeId>56cf40987635a0.60852840</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>BILAG Biologics Register (BILAG BR)</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>012837F6-3106-4988-8906-8D8117B716CC</gtr:id><gtr:title>Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c78086e1d9a514b1deee74b5fe98d82"><gtr:id>8c78086e1d9a514b1deee74b5fe98d82</gtr:id><gtr:otherNames>Md Yusof MY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5aa91264e4b307.15664916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12E9A428-686F-40EF-B375-A8DBC1E04F80</gtr:id><gtr:title>Inter-observer variability of the histological classification of lupus glomerulonephritis in children.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c59e7c89cf935ba8559cf2dfe38b2bef"><gtr:id>c59e7c89cf935ba8559cf2dfe38b2bef</gtr:id><gtr:otherNames>Oni L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9bfba88dd7.04102549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AC37AEB-8EA2-4358-ACAD-E272EE90EE94</gtr:id><gtr:title>The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0481b31dd3208e077a1b3a060bfa726"><gtr:id>d0481b31dd3208e077a1b3a060bfa726</gtr:id><gtr:otherNames>McCarthy EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5aa912662851a1.59927797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF42B7CB-8CA9-4FDB-AD9F-8E20E512E16E</gtr:id><gtr:title>Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE Cohort Study.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f164f406870447f5f9ef463859f7e3af"><gtr:id>f164f406870447f5f9ef463859f7e3af</gtr:id><gtr:otherNames>Smith EMD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9bfbddc2d9.62094270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ACCC18F-8FF8-4C5E-8B5B-691AD1C481E0</gtr:id><gtr:title>Differences in disease phenotype and severity in SLE across age groups.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f11a4dbc2eb1937d1551b83e218de4ed"><gtr:id>f11a4dbc2eb1937d1551b83e218de4ed</gtr:id><gtr:otherNames>Ambrose N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9c6721bbb7.29645280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F398BA4C-239B-4143-8785-BC254A159F5A</gtr:id><gtr:title>International validation of a urinary biomarker panel for identification of active lupus nephritis in children.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c5e194cfbb32ba48b183d77093dc0c7"><gtr:id>6c5e194cfbb32ba48b183d77093dc0c7</gtr:id><gtr:otherNames>Smith EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>5a9e9bff20e6f2.88488801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3112F8F4-4953-41ED-ABFE-4A42B2B7A3AF</gtr:id><gtr:title>Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: a longitudinal analysis.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4785c2b05ff41d70d74f0d01a7bd8435"><gtr:id>4785c2b05ff41d70d74f0d01a7bd8435</gtr:id><gtr:otherNames>Lythgoe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9bfc331ae5.24994627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCBE0703-1A32-41E2-9005-D3F3C1B4077E</gtr:id><gtr:title>Paediatric rheumatology in 2017: Child-centred research is the key to progress.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc7acbd961f1a0e49515998a74a1c839"><gtr:id>cc7acbd961f1a0e49515998a74a1c839</gtr:id><gtr:otherNames>Beresford MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>5a9e9c3ab5adf0.01256008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B227381-7965-4F73-9C4E-8EBF6542B25A</gtr:id><gtr:title>The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0481b31dd3208e077a1b3a060bfa726"><gtr:id>d0481b31dd3208e077a1b3a060bfa726</gtr:id><gtr:otherNames>McCarthy EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5aa91265ed0f34.29716239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>399B5007-7964-4B78-BECB-FE546F541D32</gtr:id><gtr:title>European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfe167cedab38ff8036722dc941c0118"><gtr:id>cfe167cedab38ff8036722dc941c0118</gtr:id><gtr:otherNames>Groot N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a9e9bfd4520a3.09599352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC45C909-B6A2-4762-A3F7-4F37FA0B59A8</gtr:id><gtr:title>Differential changes in gene expression in human neutrophils following TNF-a stimulation: Up-regulation of anti-apoptotic proteins and down-regulation of proteins involved in death receptor signaling.</gtr:title><gtr:parentPublicationTitle>Immunity, inflammation and disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e30a5d76fb7188e97dd75589b4d8e6ad"><gtr:id>e30a5d76fb7188e97dd75589b4d8e6ad</gtr:id><gtr:otherNames>Chiewchengchol D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-4527</gtr:issn><gtr:outcomeId>5a9e9c68298313.66766092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D627709-635A-4705-8364-6E1D6F15D3E0</gtr:id><gtr:title>Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/380f16a8f55681108c12fc23657cf188"><gtr:id>380f16a8f55681108c12fc23657cf188</gtr:id><gtr:otherNames>Patel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9c67776758.42703104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>407AB630-A2BA-47F7-9577-B61AD04EBC06</gtr:id><gtr:title>Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/650ee7de04c6d8b80400e58b0ddbe3bc"><gtr:id>650ee7de04c6d8b80400e58b0ddbe3bc</gtr:id><gtr:otherNames>Midgley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5a9e9c68082710.99309857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9037D2DC-25B2-464F-A33E-8D3D98126A09</gtr:id><gtr:title>European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfe167cedab38ff8036722dc941c0118"><gtr:id>cfe167cedab38ff8036722dc941c0118</gtr:id><gtr:otherNames>Groot N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a9e9bfd05bdd8.56114974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40031852-6F2B-4CC7-866B-D8EB5ACC23DB</gtr:id><gtr:title>Optimising the use of medicines to reduce acute kidney injury in children and babies.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c59e7c89cf935ba8559cf2dfe38b2bef"><gtr:id>c59e7c89cf935ba8559cf2dfe38b2bef</gtr:id><gtr:otherNames>Oni L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5a9e9bfc84a366.57054150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FCC26DD-1333-4700-8EE2-8386749B4DF9</gtr:id><gtr:title>Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.</gtr:title><gtr:parentPublicationTitle>Paediatric drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1556a725a3fb60e2dcec8c65306243d6"><gtr:id>1556a725a3fb60e2dcec8c65306243d6</gtr:id><gtr:otherNames>Thorbinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1174-5878</gtr:issn><gtr:outcomeId>5a9e9c67c79596.32063997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8417CA1C-1765-458D-AF06-625300A41B8B</gtr:id><gtr:title>Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature.</gtr:title><gtr:parentPublicationTitle>American journal of clinical dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7efd5d2b082e526b2dd97d41f461a206"><gtr:id>7efd5d2b082e526b2dd97d41f461a206</gtr:id><gtr:otherNames>Rodsaward P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1175-0561</gtr:issn><gtr:outcomeId>5a9e9bfea24d25.51887554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>762600F5-993D-4A7D-9F30-BFA32761A3AB</gtr:id><gtr:title>Urinary biomarkers in childhood lupus nephritis.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f164f406870447f5f9ef463859f7e3af"><gtr:id>f164f406870447f5f9ef463859f7e3af</gtr:id><gtr:otherNames>Smith EMD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>5a9e9bfedf3c72.13646209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>088BC8DB-4BB5-458D-8841-E0BCEE16DEE8</gtr:id><gtr:title>Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b44b82e789d0c7d8753d98827743bf1b"><gtr:id>b44b82e789d0c7d8753d98827743bf1b</gtr:id><gtr:otherNames>Ramanathan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a9e9c3b0634c8.30486703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63C7B73D-8C3A-47EE-8CA2-CBD78BC1395D</gtr:id><gtr:title>The economic case for precision medicine</gtr:title><gtr:parentPublicationTitle>Expert Review of Precision Medicine and Drug Development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555e7540bab196ec0dc80e38eb968921"><gtr:id>555e7540bab196ec0dc80e38eb968921</gtr:id><gtr:otherNames>Gavan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a678fc24a9670.42259534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>664AABCB-16DC-4C74-8486-18B098A2991F</gtr:id><gtr:title>European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfe167cedab38ff8036722dc941c0118"><gtr:id>cfe167cedab38ff8036722dc941c0118</gtr:id><gtr:otherNames>Groot N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a9e9bfb6edea0.46232613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E0FF374-5919-45C9-9513-84DCEBA31CA6</gtr:id><gtr:title>Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee9d266603887a6461a3490e100d7d83"><gtr:id>ee9d266603887a6461a3490e100d7d83</gtr:id><gtr:otherNames>Kuemmerle-Deschner JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a9e9bffb81ee6.75641047</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M01665X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>